Therapeutics News and Research

RSS

Study: Nanoparticles can prevent nickel-induced dermatitis

Tiny particles only billionths of a meter in diameter-about two thousand would fit across the width of a human hair-could offer big hope in a small package to the many millions of people who are allergic to the nickel in everything from jewelry to coins and cell phones, say scientists at Brigham and Women's Hospital.

4 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

Researchers study role of acetylation in Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer's disease and related disorders. The findings were published in the latest issue of Nature Communications.

1 Apr 2011

CPRIT awards $12.6M grant to Gulf Coast Consortia to develop new cancer treatments

The Gulf Coast Consortia has been awarded a grant of more than $12.6 million from the Cancer Prevention Research Institute of Texas to launch a collaborative program that brings together researchers with the common purpose of developing new cancer treatments.

1 Apr 2011

Broad opportunities for covalent drugs

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs".

1 Apr 2011

California State Controller urges Merck, Tibotec and ViiV to reduce AIDS drug prices

Today AIDS Healthcare Foundation (AHF) announced that California State Controller John Chiang has sent letters to the CEOs of Merck & Co., Tibotec Therapeutics and ViiV Healthcare, asking the companies to reduce the price of their HIV/AIDS medications for California and its AIDS Drug Assistance Program (ADAP).

1 Apr 2011

LIFE Biosystems to present MASE data at AACR annual meeting

Adverse events, or side effects, have traditionally been viewed as an unavoidable consequence in the therapeutic treatment of cancer patients. Yet sufficient data exists to study the relationship between molecular mechanisms, and drug-induced phenotypes to learn about - and even predict - adverse events in patients.

1 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Akela reports net income of $1.5 million for three months ended December 31, 2010

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months and year ended December 31, 2010.

1 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Nile's post-acute development program for cenderitide, which has the goal of reducing cardiovascular mortality and cardiovascular re-hospitalization in the post-acute period in patients with acute decompensated heart failure.

31 Mar 2011

Protox reports net loss of $4.5 million for year ended December 31, 2010

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the year ended December 31, 2010.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the fourth quarter and full-year ended December 31, 2010, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL and established 2011 financial guidance.

31 Mar 2011

Cancer Commons researchers publish MDMM paper in PLoS ONE journal

Cancer Commons, an initiative of CollabRx, a provider of information technology to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model of melanoma which classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

31 Mar 2011

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Cellectis, the genome engineering specialist, has announced its consolidated financial results for the financial year ended December 31, 2010.

31 Mar 2011

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-5902 during a poster session at the American Association for Cancer Research 102nd Annual Meeting being held in Orlando, Florida, April 2-6, 2011, at the Orange County Convention Center.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Therapeutics News and Research

Study: Nanoparticles can prevent nickel-induced dermatitis

Experts must monitor new antiviral compounds for HCV treatment

NeoStem revenues increase 13% for the year ended December 31, 2010

ACADIA extends collaboration agreement with Allergan for drug discovery platform

Researchers study role of acetylation in Alzheimer's disease

CPRIT awards $12.6M grant to Gulf Coast Consortia to develop new cancer treatments

Broad opportunities for covalent drugs

California State Controller urges Merck, Tibotec and ViiV to reduce AIDS drug prices

LIFE Biosystems to present MASE data at AACR annual meeting

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

Akela reports net income of $1.5 million for three months ended December 31, 2010

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Protox reports net loss of $4.5 million for year ended December 31, 2010

RXi Pharmaceuticals to acquire Apthera

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Cancer Commons researchers publish MDMM paper in PLoS ONE journal

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News